News and Announcements
OncoSil Medical Annual Report 2016
- Published September 16, 2016 11:29AM UTC
- Publisher Wholesale Investor
- Categories Company Updates
12th September 2016, ASX Announcement
FY16 Achievements Delivered
September 2015
Submission of CE Mark application for OncoSil™
October 2015
OncoSil™ CE Mark application granted Fast Track review status
December 2015
Investigational Device Exemption (IDE) submitted to the U.S. FDA for OncoPac-1 clinical study
January 2016
Chris Roberts appointed Independent Non-Executive Director
February 2016
$10 million private placement to Regal Funds Management
March-April 2016
Q-Submissions meeting with FDA
Responses to CE Mark and FDA questions
May 2016
OncoSil Medical completes hiring of senior management for Leadership team
To view the full announcement, please click on the button below.